Purdue opts in and plans to launch Transcept’s Intermezzo in the US in 2Q 2012
This article was originally published in Scrip
Executive Summary
Transcept Pharmaceuticals said that Purdue Pharma has exercised its option to commercialise the company’s middle-of-the-night sleep aid, Intermezzo (zolpidem tartrate sublingual tablet), in the US. A launch is planned for the second quarter of 2012, with a sales force aimed at primary care physicians, pain specialists and psychiatrists.